Sourced from:Manufacturer Authorized Distributor
Quick Summary
Bonitar 100mg Tablet
Last updated on 08 Jun 2026 | 06:06 AM (IST)
₹797
MRP: ₹937.5
(You Save ₹140.5)
10 TABLET(s) IN A STRIP
Sourced from:Manufacturer Authorized Distributor
15% OFF
₹797
MRP: ₹937.50
Inclusive of all taxes
15% Off
Dispatch: Today
Order In: 0h 0m 0s
0h 0m 0s
Order before timer ends to ensure your medicine is dispatched at...
Substitutes
Bosutris 100mg Tablet
MYLAN PHARMACEU...
₹ 45.88/tablet
42% cheaper
Bosuvi 100mg Tablet
GLENMARK PHARMA...
₹ 66.05/tablet
17% cheaper
Introduction to Bonitar 100mg Tablet
Bonitar 100mg Tablet contains the active ingredient Bosutinib. It belongs to the group of medications called Tyrosine kinase inhibitors. It is indicated to treat adult patients with a type of leukaemia known as Philadelphia chromosome-positive (Ph-positive) Chronic Myeloid Leukaemia (CML) who have been newly diagnosed or for whom earlier CML treatments have either failed or have not worked or are not suitable. Philadelphia chromosome-positive chronic myelogenous leukaemia is a blood cancer in which the body produces too many of a specific kind of white blood cell called granulocytes.
Low white blood cell count (leukopenia), headache, shortness of breath, joint pain, dizziness, cough, back pain, decreased appetite, respiratory tract infection, raised blood pressure, ringing in the ears (tinnitus), itching, acne, dehydration, taste change, sensitivity to light and fluid on lungs are the common side effects of Bonitar 100mg Tablet. Inform your doctor if any of these symptoms disturb you or persist.
Inform your physician if you are allergic to the Bonitar 100mg Tablet or its ingredients. Before taking this medication, report to your doctor if you have heart problems, bleeding problems, kidney and liver disorders, infection, or diarrhoea. It is not recommended for children under the age of 18. Limit your time outside and use sunscreen if you must go outside, as this medicine can make you more sensitive to the sun or UV rays.
Uses of Bonitar 100mg Tablet
- Treatment of Philadelphia chromosome-positive chronic myelogenous leukaemia (Ph+ CML).
Therapeutic Effects of Bonitar 100mg Tablet
Bosutinib in Bonitar 100mg Tablet works by inhibiting the activity of an enzyme called Bcr-Abl kinase that promotes the growth and spread of blood cancer (Ph+ CML). This helps to slow or stop the growth and spread of cancer cells.
Interaction of Bonitar 100mg Tablet with other drugs
Bonitar 100mg Tablet contains bosutinib, a tyrosine kinase inhibitor used to treat Philadelphia chromosome-positive chronic myeloid leukaemia. It may interact with medications such as proton pump inhibitors (e.g., pantoprazole, esomeprazole), CYP3A inhibitors (e.g., ritonavir, itraconazole), and CYP3A inducers (e.g., rifampicin, phenytoin). These interactions can affect bosutinib's efficacy and safety. Consult your healthcare provider before combining Bonitar with other medications.
More Information about Bonitar 100mg Tablet
- Keep Bonitar 100mg Tablet out of sight and reach of children.
- Store at a temperature not exceeding 30°C, protected from moisture.
How to consume Bonitar 100mg Tablet
Take Bonitar 100mg Tablet in the dose and duration prescribed by your doctor. Take this medicine once a day with food. Swallow it whole and avoid breaking or crushing the tablet. Do not handle or touch the broken tablets.
Safety Advice for Bonitar 100mg Tablet
Breast Feeding
Avoid breastfeeding while taking Bonitar 100mg Tablet, as it is not known whether it passes into the breast milk and harms your baby. Consult the doctor before taking this medication.
Alcohol
Drinking a small amount of alcohol does not affect the safety or usefulness of Bonitar 100mg Tablet. As a precautionary measure, limit or avoid alcohol with this medication.
Liver
Tell your doctor if you have a history of liver problems, including hepatitis, before taking Bonitar 100mg Tablet. Your doctor will perform blood tests to evaluate your liver function.
Lungs
Inform your doctor if you have any lung conditions before starting treatment with Bonitar 100mg Tablet.
Driving
Taking Bonitar 100mg Tablet can cause dizziness, blurred vision, or unusual tiredness. Do not drive if you feel unwell.
Pregnancy
Bonitar 100mg Tablet is unsafe to use during pregnancy as it could cause potential harm to a developing baby. Consult the doctor before taking this medicine, and it will be given to you if clearly needed. Use effective birth control during and for 30 days (one month) after the last dose.
Side Effects of Bonitar 100mg Tablet
Side effects are unwanted symptoms caused by medicines. Even though all medications cause side effects, not everyone gets them.
Serious:
- Blood disorders (bleeding, fever, bruising)
- Stomach problems (stomach pain, vomiting, diarrhoea, constipation, nausea)
- Hepatitis B reactivation
- Severe skin reactions
- Liver problems (yellowing of white part of eyes and skin, tea-colored urine)
- Heart problems (loss of consciousness, irregular heartbeat)
Common:
- Low white blood cell count (leukopenia)
- Headache, dizziness
- Cough, shortness of breath
- Joint pain, back pain
- Decreased appetite
- Respiratory tract infection
- Increase in blood pressure
- Ringing in the ears (tinnitus)
- Itching, acne
- Dehydration
- Taste change
- Sensitivity to light
- Fluid on lungs
Word of Advice
Women taking Bonitar 100mg Tablet are advised to use effective contraceptives like birth control during treatment and for one month (30 days) after the last dose. Check with your healthcare provider and inform them if you take any other medications, including over-the-counter and prescription medicines, vitamins, and herbal supplements. It is suggested to use sunscreen with a good sun protection factor (SPF) because you are sensitive to sun or UV rays while taking this medication. Do not eat or drink grapefruit-containing food products as this may increase the blood level in your body.
FAQs about Bonitar 100mg Tablet
Q1.
Bonitar 100mg Tablet a chemotherapy medication?
Yes, Bonitar 100mg Tablet is a chemotherapy medication that is indicated to treat Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML) in adults.
Q2.
What class of medication is Bonitar 100mg Tablet?
Bonitar 100mg Tablet belongs to the class of medications called tyrosine kinase inhibitors.
Q3.
Can you crush Bonitar 100mg Tablet?
No, Bonitar 100mg Tablet should not be crushed or broken. It must be swallowed whole with a glass of water. Do not handle or touch the broken tablets.
Q4.
What is the best time to take Bonitar 100mg Tablet?
It is best to take Bonitar 100mg Tablet once a day without food. Take the tablet at the same time every day for the better results.
Q5.
What happens if I miss my dose of Bonitar 100mg Tablet?
Take the recommended dose if you miss a dose of Bonitar 100mg Tablet by less than 12 hours. If you miss the dose by more than 12 hours, skip the missing dose and start your next dose at the regular time.
Q6.
What should be avoided in Bonitar 100mg Tablet?
Grapefruit, its juices, and supplement that contain grapefruit extract should be avoided during treatment with Bonitar 100mg Tablet as it raises the blood level in your body.
Q7.
Can children use Bonitar 100mg Tablet?
No, Bonitar 100mg Tablet is not recommended for usage in children under 18.
Q8.
Who is contraindicated to take Bonitar 100mg Tablet?
Patients who have experienced allergic reactions (hypersensitivity) to Bonitar 100mg Tablet or have heart or bleeding problems, kidney or liver disorders, and pregnant and breastfeeding women should not use Bonitar 100mg Tablet.
Fact Box of Bonitar 100mg Tablet
Molecule name: Bosutinib
| Therapeutic class: Tyrosine kinase inhibitors |
Pharmacological class: Antineoplastics | Indications: Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML). |
References
- Pfizer Europe MA EEIG, Electronic medicines compendium (EMC), [ Revised on May 2022] [ Accessed on 21 November 2022], https://www.medicines.org.uk/emc/files/pil.3147.pdf
- Pfizer, US Food and Drug Administration, [ Revised on April 2017] [ Accessed on 21 November 2022], https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/20334s007s008lbl.pdf
- Gunhild keller et al; Bosutinib; Recent Results in Cancer Research; Published on 2010; Accessed on 21/11/2022; https://pubmed.ncbi.nlm.nih.gov/20072835/
Disclaimer
MrMed’s primary intention is to ensure that its consumers get information that is reviewed by experts, accurate and trustworthy. The information and contents of this website are for informational purposes only. They are not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please seek the advice of your doctor and discuss all your queries related to any disease or medicine. Do not disregard professional medical advice or delay in seeking it because of something you have read on MrMed. Our mission is to support, not replace, the doctor-patient relationship.
Did you find this information helpful?
Author Details
Written By
Guruvigneshwari M.
M. Pharm
Reviewed By
Dr. Tejashwin Adiga
MBBS
Last updated : 08 Jun 2026 | 06:06 AM (IST)
Want to know more?
Read Our Editorial Policy
